SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Fundamental Analysis
NASDAQ:SUPN - Nasdaq - US8684591089 - Common Stock - Currency: USD
SUPN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. SUPN gets an excellent profitability rating and is at the same time showing great financial health properties. SUPN has a decent growth rate and is not valued too expensively. These ratings could make SUPN a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
SUPN had positive earnings in the past year.
In the past year SUPN had a positive cash flow from operations.
SUPN had positive earnings in each of the past 5 years.
In the past 5 years SUPN always reported a positive cash flow from operatings.
1.2 Ratios
SUPN has a Return On Assets of 4.60%. This is amongst the best in the industry. SUPN outperforms 88.21% of its industry peers.
Looking at the Return On Equity, with a value of 6.01%, SUPN belongs to the top of the industry, outperforming 86.15% of the companies in the same industry.
SUPN has a Return On Invested Capital of 4.82%. This is amongst the best in the industry. SUPN outperforms 82.56% of its industry peers.
SUPN had an Average Return On Invested Capital over the past 3 years of 2.70%. This is significantly below the industry average of 14.87%.
The last Return On Invested Capital (4.82%) for SUPN is above the 3 year average (2.70%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.6% | ||
| ROE | 6.01% | ||
| ROIC | 4.82% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
1.3 Margins
The Profit Margin of SUPN (9.27%) is better than 86.67% of its industry peers.
SUPN's Profit Margin has declined in the last couple of years.
SUPN has a Operating Margin of 12.49%. This is amongst the best in the industry. SUPN outperforms 83.59% of its industry peers.
SUPN's Operating Margin has declined in the last couple of years.
The Gross Margin of SUPN (89.75%) is better than 93.33% of its industry peers.
In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.49% | ||
| PM (TTM) | 9.27% | ||
| GM | 89.75% |
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SUPN is destroying value.
The number of shares outstanding for SUPN has been increased compared to 1 year ago.
SUPN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
SUPN has an Altman-Z score of 5.14. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
SUPN has a better Altman-Z score (5.14) than 78.97% of its industry peers.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.14 |
ROIC/WACC0.49
WACC9.91%
2.3 Liquidity
A Current Ratio of 2.44 indicates that SUPN has no problem at all paying its short term obligations.
With a Current ratio value of 2.44, SUPN perfoms like the industry average, outperforming 43.59% of the companies in the same industry.
A Quick Ratio of 2.26 indicates that SUPN has no problem at all paying its short term obligations.
SUPN's Quick ratio of 2.26 is in line compared to the rest of the industry. SUPN outperforms 47.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.44 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.54%, which is quite impressive.
The Earnings Per Share has been growing slightly by 3.78% on average over the past years.
The Revenue has grown by 11.81% in the past year. This is quite good.
The Revenue has been growing by 11.00% on average over the past years. This is quite good.
EPS 1Y (TTM)98.54%
EPS 3Y37.36%
EPS 5Y3.78%
EPS Q2Q%69.23%
Revenue 1Y (TTM)11.81%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%4.3%
3.2 Future
SUPN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.42% yearly.
Based on estimates for the next years, SUPN will show a small growth in Revenue. The Revenue will grow by 7.28% on average per year.
EPS Next Y-31.87%
EPS Next 2Y-2.58%
EPS Next 3Y10.68%
EPS Next 5Y15.42%
Revenue Next Year-1.68%
Revenue Next 2Y4.95%
Revenue Next 3Y7.11%
Revenue Next 5Y7.28%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SUPN is valuated correctly with a Price/Earnings ratio of 12.18.
Compared to the rest of the industry, the Price/Earnings ratio of SUPN indicates a rather cheap valuation: SUPN is cheaper than 89.23% of the companies listed in the same industry.
SUPN's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.30.
With a Price/Forward Earnings ratio of 13.74, SUPN is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SUPN indicates a somewhat cheap valuation: SUPN is cheaper than 79.49% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.76. SUPN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.18 | ||
| Fwd PE | 13.74 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SUPN is valued cheaper than 94.36% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SUPN is valued cheaply inside the industry as 89.74% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.35 | ||
| EV/EBITDA | 6.39 |
4.3 Compensation for Growth
The excellent profitability rating of SUPN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.22
EPS Next 2Y-2.58%
EPS Next 3Y10.68%
5. Dividend
5.1 Amount
SUPN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
33.12
-0.02 (-0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners108.96%
Inst Owner Change0%
Ins Owners4.08%
Ins Owner Change2.14%
Market Cap1.85B
Analysts78.18
Price Target39.78 (20.11%)
Short Float %7.57%
Short Ratio7.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.36%
Min EPS beat(2)15.55%
Max EPS beat(2)77.18%
EPS beat(4)3
Avg EPS beat(4)60.49%
Min EPS beat(4)-9.5%
Max EPS beat(4)158.74%
EPS beat(8)5
Avg EPS beat(8)41.41%
EPS beat(12)6
Avg EPS beat(12)18.01%
EPS beat(16)9
Avg EPS beat(16)24.4%
Revenue beat(2)1
Avg Revenue beat(2)4.64%
Min Revenue beat(2)-0.71%
Max Revenue beat(2)9.98%
Revenue beat(4)3
Avg Revenue beat(4)7.41%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)10.86%
Revenue beat(8)5
Avg Revenue beat(8)3.48%
Revenue beat(12)8
Avg Revenue beat(12)2.47%
Revenue beat(16)11
Avg Revenue beat(16)2.27%
PT rev (1m)0.52%
PT rev (3m)0.52%
EPS NQ rev (1m)-6%
EPS NQ rev (3m)2.92%
EPS NY rev (1m)-18.23%
EPS NY rev (3m)-13.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)0.98%
Revenue NY rev (3m)1.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.18 | ||
| Fwd PE | 13.74 | ||
| P/S | 2.78 | ||
| P/FCF | 11.35 | ||
| P/OCF | 11.3 | ||
| P/B | 1.8 | ||
| P/tB | 4.51 | ||
| EV/EBITDA | 6.39 |
EPS(TTM)2.72
EY8.21%
EPS(NY)2.41
Fwd EY7.28%
FCF(TTM)2.92
FCFY8.81%
OCF(TTM)2.93
OCFY8.85%
SpS11.93
BVpS18.41
TBVpS7.35
PEG (NY)N/A
PEG (5Y)3.22
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.6% | ||
| ROE | 6.01% | ||
| ROCE | 7.83% | ||
| ROIC | 4.82% | ||
| ROICexc | 8.53% | ||
| ROICexgc | N/A | ||
| OM | 12.49% | ||
| PM (TTM) | 9.27% | ||
| GM | 89.75% | ||
| FCFM | 24.45% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score8
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1% | ||
| Cap/Sales | 0.12% | ||
| Interest Coverage | -758.75 | ||
| Cash Conversion | 100.39% | ||
| Profit Quality | 263.83% | ||
| Current Ratio | 2.44 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 5.14 |
F-Score8
WACC9.91%
ROIC/WACC0.49
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)98.54%
EPS 3Y37.36%
EPS 5Y3.78%
EPS Q2Q%69.23%
EPS Next Y-31.87%
EPS Next 2Y-2.58%
EPS Next 3Y10.68%
EPS Next 5Y15.42%
Revenue 1Y (TTM)11.81%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%4.3%
Revenue Next Year-1.68%
Revenue Next 2Y4.95%
Revenue Next 3Y7.11%
Revenue Next 5Y7.28%
EBIT growth 1Y1176.19%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year84.48%
EBIT Next 3Y-11.94%
EBIT Next 5Y21.99%
FCF growth 1Y0.95%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y1.58%
OCF growth 3Y10.6%
OCF growth 5Y3.74%